Table 1 Patients’ characteristics
Patient characteristics | Age >75 years only curative intent (n = 24) | Age >75 years only palliative intent (n = 8) | Age ≤75 years (n = 39) | p valuea | |||
|---|---|---|---|---|---|---|---|
% | Median | % | Median | % | Median | ||
(IQR 25–75) | (IQR 25–75) | (IQR 25–75) | |||||
Sex | 1.000 | ||||||
Male (%) | 66.7 | 62.5 | 66.7 | ||||
Age in years | 81 | 83 | 66 | <0.001 | |||
(78–85) | (79–84) | (59–72) | |||||
ECOG | <0.001 | ||||||
0 | 17.4 | 28.6 | 73.0 | ||||
1 | 78.3 | 57.1 | 27.0 | ||||
2 | 4.3 | 14.3 | 0.0 | ||||
ACCI | 7 | 8 | 4 | <0.001 | |||
(6–8) | (6–9) | (4–5) | |||||
Histology | 0.006 | ||||||
SCC (%) | 79.2 | 66.7 | 100.0 | ||||
Adenocarcinoma (%) | 20.8 | 33.3 | 0.0 | ||||
Primary tumor extension | 0.353 | ||||||
cT1 (%) | 12.5 | 0 | 8.1 | ||||
cT2 (%) | 4.2 | 37.5 | 5.4 | ||||
cT3 (%) | 83.3 | 62.5 | 75.7 | ||||
cT4 (%) | 0 | 0 | 10.8 | ||||
Lymph node extension | 0.721 | ||||||
cN+ (%) | 83.3 | 100 | 87.2 | ||||
Distant metastasis | 0.268 | ||||||
M1 (%) | 0 | 25 | 8.3 | ||||
UICC-stage | 0.239 | ||||||
IA (%) | 8.3 | 0 | 0 | ||||
IIA (%) | 8.3 | 0 | 11.1 | ||||
IIB (%) | 8.3 | 37.5 | 11.1 | ||||
IIIA (%) | 75 | 50 | 61,1 | ||||
IIIC (%) | 0 | 0 | 8.3 | ||||
IV (%) | 0 | 12.5 | 8.3 | ||||
Grading | 0.492 | ||||||
G1 (%) | 4.2 | 0 | 0.0 | ||||
G2 (%) | 50 | 25 | 57.1 | ||||
G3 (%) | 45.8 | 75 | 42.9 | ||||
Tumor localization | 0.195 | ||||||
Upper third (%) | 26.1 | 25 | 42.1 | ||||
Middle third (%) | 43.5 | 50 | 23.7 | ||||
Lower third (%) | 30.4 | 25 | 34.2 | ||||
Tumor length (centimeter) | 5 | 7 | 5 | 0.245 | |||
(3–7) | (5–9) | (5–7) | |||||
Discontinuation of treatment (%) | 0.0 | 60 | 0.0 | ||||
Simultaneous chemotherapy (%) | 41.7 | 37.5 | 82.1 | 0.002 | |||
EQD2 (Gy) | 54 | 40 | 53 | 0.417 | |||
(53–55) | (19–46) | (53–54) | |||||
Overall dose (Gy) | 54 | 38 | 54 | 0.860 | |||
(54–56) | (20–45) | (54–54) | |||||
Daily dose (Gy) | 1.8 | 2.0 | 1.8 | 0.127 | |||
(1.8–2) | (1.8–2.5) | (1.8–1.8) | |||||